Skip to main content
. 2018 Jun 24;8(14):3932–3948. doi: 10.7150/thno.25541

Figure 6.

Figure 6

CAF-derived exosomes transfer H19 to CRC cells and promote tumor growth and oxaliplatin resistance in vivo. (A-B) Subcutaneous xenografts were established in nude mice, which were treated with vehicle or oxaliplatin (5 mg/kg). In the exosome groups, the mice were injected with the indicated exosomes. The changes of tumor volume were monitored and shown (n = 6 per group). (C) The level of H19 in tumor tissues was analyzed by qRT-PCR and was increased by CAF-exosome treatment compared with NF-exosome treatment. (D-E) Immunohistochemistry analysis of Ki-67 protein levels in xenograft tumor tissues. Treatment with CAF-exosomes increased the expression of Ki-67 under treatment with oxaliplatin. Scale bar, 50 μm. (F-G) Immunohistochemistry analysis of cleaved Caspase-3 protein levels in xenograft tumor tissues. Scale bar, 50 μm. Treatment with CAF-exosomes decreased the protein expression of cleaved Caspase-3 under the treatment of oxaliplatin. (H-I) TUNEL apoptosis assay analysis of cell apoptosis in tumor tissues. Scale bar, 25 μm. Error bars, SD. *P < 0.05, **P < 0.01, ***P < 0.001.